Lymphoma, T-Cell, Cutaneous - 27 Studies Found
Completed |
: Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL) : Lymphoma, T-Cell, Cutaneous : 2011-09-09 :
|
Completed |
: A Study of the Histone Deacetylase Inhibitor (HDACi) Quisinostat (JNJ-26481585) in Patients With Previously Treated Stage Ib-IVa Cutaneous T-cell Lymphoma : Lymphoma, T-Cell, Cutaneous : 2011-11-29 : Drug: Quisinostat, 12 mg Participants will receive quisinostat 12 mg capsule orally (by mouth) on Days 1 |
Completed |
: CPG 7909 in Patients With Cutaneous T-Cell Lymphoma : Lymphoma, T-Cell, Cutaneous : 2002-08-08 :
|
Completed |
: Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL) : Lymphoma, T-Cell, Cutaneous : 2005-09-13 : Drug: ONTAK (denileukin difitox, DAB389IL-2) |
No longer available |
: Compassionate Use of Vorinostat for the Treatment of Patients With Advanced Cutaneous T-Cell Lymphoma (0683-042) : Lymphoma, T-Cell, Cutaneous : 2007-01-05 : Drug: Comparator: vorinostat Each patient will receive open-label vorinostat 400 mg q.d. capsules. Treat |
No longer available |
: Open-label Pilot Study of Lenalidomide (Revlimid) as Adjuvant Treatment for Refractory Cutaneous T Cell Lymphoma : Cutaneous T Cell Lymphoma : 2010-05-25 : Drug: Lenalidomide Lenalidomide Starting Dose Based on Renal Function at Study Entry Baseline Calculated |
Recruiting |
: Micro Needle Array-Doxorubicin (MNA-D) in Patients With Cutaneous T-cell Lymphoma (CTCL) : Cutaneous T Cell Lymphoma : 2014-07-10 : Drug: Micro needle array-Doxorubicin (MNA-D) MNA-D patches will be applied to 3-4 CTCL skin patches or p |
Completed |
: Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma : Cutaneous T-Cell Lymphoma : 2007-01-22 : Drug: Panobinostat Other Name: LBH589 |
Withdrawn |
: Trial of Curcumin in Cutaneous T-cell Lymphoma Patients : Cutaneous T-cell Lymphoma : 2009-08-27 :
|
Completed |
: A Study of APO866 for the Treatment of Cutaneous T-cell Lymphoma : Cutaneous T-cell Lymphoma : 2007-02-05 : Drug: APO866 APO866 is administered as 0.126 mg/m²/hr for 4 consecutive days (96 hours), every 3 we |